Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $75.00

Keros Therapeutics, Inc. (NASDAQ:KROS) has been assigned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $75.00.

A number of analysts recently issued reports on the company. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Wedbush reissued an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Guggenheim lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Finally, Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating on the stock.

Keros Therapeutics Trading Down 2.7 %

KROS stock opened at $12.48 on Friday. Keros Therapeutics has a 1-year low of $12.22 and a 1-year high of $73.00. The firm has a market cap of $505.53 million, a PE ratio of -2.40 and a beta of 1.43. The business’s 50-day moving average price is $39.77 and its two-hundred day moving average price is $47.88.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.33) EPS. On average, analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Hedge funds have recently bought and sold shares of the business. KBC Group NV grew its stake in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics in the third quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics in the 2nd quarter worth $128,000. Finally, LMR Partners LLP purchased a new position in Keros Therapeutics during the 3rd quarter valued at about $213,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.